SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 2

Insulin-like growth factor-1 receptor expression in pediatric tumors: a comparative immunohistochemical study

Derya ÖZYÖRÜK
Suna EMİR
Esra KARAKUŞ
Ayper KAÇAR
Resul KARAKUŞ
Pages
419–423
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

IGF-1R could be included among confirmatory markers for ESTs and, from a therapeutic viewpoint, ESTs should also beexamined for IGF-1R expression for beneficial regimens.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Insulin-like growth factor-1 receptor (IGF-1R) is a pivotal receptor tyrosine kinase involved in the cell cycle andmalignant tumor transformation.
📊
Key Findings & Data:We aimed to determine the expression of IGF1R in different pediatric tumors and to shed light on possible new indications of anti-IGF-1R treatment approaches.Materials and methods: A total of 147 specimens were analyzed according to their expression of IGF-1R.
💡
Conclusion & Impact:IGF-1R could be included among confirmatory markers for ESTs and, from a therapeutic viewpoint, ESTs should also beexamined for IGF-1R expression for beneficial regimens.
🔬Design:Research Article
📍Scope:147 specimens
⚙️Variables:Domain Parameters

Abstract

Background/aim: Insulin-like growth factor-1 receptor (IGF-1R) is a pivotal receptor tyrosine kinase involved in the cell cycle andmalignant tumor transformation. It is differentially expressed in various types of tumors. We aimed to determine the expression of IGF1R in different pediatric tumors and to shed light on possible new indications of anti-IGF-1R treatment approaches.Materials and methods: A total of 147 specimens were analyzed according to their expression of IGF-1R. Specimens includedthose from rhabdomyosarcomas, Wilms tumors, Ewing sarcoma/primitive neuroectodermal tumors, peripheral neuroblastictumors, acute lymphoblastic lymphoma, Hodgkin lymphoma, Burkitt lymphoma, retinoblastoma, pleuropulmonary blastoma,Langerhans cell histiocytosis, endodermal sinus tumors (ESTs), and myeloid sarcoma. Analysis was performed on tissue sections byimmunohistochemically staining for IGF-1R expression.Results: All six specimens of EST cases showed positivity for IGF-R1. Additionally, about 56% of the Hodgkin lymphoma, 80% of therhabdomyosarcoma, and 70% of the Wilms tumor specimens showed positivity for IGF-R1 expression.Conclusion: All ESTs examined in our study expressed IGF-1R and to our knowledge this is the first report regarding ESTs and IGF-1Rexpression. IGF-1R could be included among confirmatory markers for ESTs and, from a therapeutic viewpoint, ESTs should also beexamined for IGF-1R expression for beneficial regimens.

🔖

Cite This Article

ÖZYÖRÜK, D., EMİR, S., KARAKUŞ, E., KAÇAR, A., KARAKUŞ, R. (2022). Insulin-like growth factor-1 receptor expression in pediatric tumors: a comparative immunohistochemical study. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 2, 419–423. https://ajindex.com/articles/610142

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Reinmuth N, Kloos S, Warth A, Risch A, Muley T, Hoffmann H, Thomas M, Meister M. Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. Hum Pathol 2014; 45: 1162-1168.
  2. Tran TN, Selinger CI, Yu B, Ng CC, Kohonen-Corish MR, McCaughan B, Kennedy C, O’Toole SA, Cooper WA. Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. J Clin Pathol 2014; 67: 985-991.
  3. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-2950.
  4. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238-10246.
  5. LeRoy EC, Moore JH, Hu C, Martínez ME, Lance P, Duggan D, Thompson PA. Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia. Hum Genet 2011; 129: 503-512.
  6. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing’s sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 2011; 6: e26060. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP et al. A phase 2 trial of R1507, a monoclonal antibody to the insulinlike growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 2014; 120: 2448-2456.
  7. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010; 21: 610-618. van Gaal JC, Roeffen MH, Flucke UE, van der Laak JA, van der Heijden G, de Bont ES, Suurmeijer AJ, Versleijen-Jonkers YM, van der Graaf WT. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. Eur J Cancer 2013; 49: 3462-3470.
  8. Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pri